FLT3.jpg
lincoln center.jpg
FLT3.jpg

Crenogist Intro


Crenolanib

A next-gen tyrosine kinase inhibitor for use in PDGRFA-D842V GIST

SCROLL DOWN

Crenogist Intro


Crenolanib

A next-gen tyrosine kinase inhibitor for use in PDGRFA-D842V GIST


CRENOGIST (ARO-012): An ongoing STUDY FOR D842V MUTANT GIST

  • This is a Phase III clinical trial of crenolanib in patients with advanced or metastatic gastrointestinal stromal tumors (GIST) with a specific mutation (D842V) in the PDGFRA gene.
  • This study is currently recruiting at multiple centers in the United States and Europe.
  • This study aims to find out how safe and effective crenolanib is, compared with a placebo, in prolonging the amount of time patients avoid disease progression.

For more information about the study, please contact a study site or visit clinicaltrials.gov/ct2/show/NCT02847429


Copy of Crenolanib


Copy of Crenolanib



Crenolanib.svg.png

THERE ARE SEVERAL ATTRIBUTES THAT SET CRENOLANIB APART FROM OTHER THERAPEUTIC OPTIONS

  1. Crenolanib has shown benefit in PDGFRA-mutant GIST.

  2. Patients who progress after treatment with prior TKIs may still remain sensitive to crenolanib.

  3. Crenolanib has favorable pharmacokinetics and does not accumulate with repeated dosing.


Copy of Recent Peer-Reviewed Publications


Copy of Recent Peer-Reviewed Publications


RECENT PEER-REVIEWED PUBLICATIONS



lincoln center.jpg

Copy of For More Information


For more information visit clinicaltrials.gov or contact us directly.

5420 LBJ Freeway, Suite 410
Dallas, TX 75240
Email: info@arogpharma.com

Copy of For More Information


For more information visit clinicaltrials.gov or contact us directly.

5420 LBJ Freeway, Suite 410
Dallas, TX 75240
Email: info@arogpharma.com